Ladenburg starts Novocure with a Buy, sees ‘path to profitability’

As previously reported, Ladenburg initiated coverage of Novocure (NVCR) with a Buy rating and $30 price target The firm cites a positive outlook for Optune Gio to retain “healthy market share” in glioblastoma, a path to profitability based on uptake of Optune Lua in treatment of second-line non small cell lung cancer and evidence supporting Tumor Treating Fields as a platform technology for various solid tumors.